BioLife Solutions Inc (BLFS)vsResMed Inc (RMD)
BLFS
BioLife Solutions Inc
$38.61
0.00%
HEALTHCARE · Cap: $1.89B
RMD
ResMed Inc
$239.77
+0.33%
HEALTHCARE · Cap: $33.61B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 5199% more annual revenue ($5.65B vs $106.69M). BLFS leads profitability with a 54.3% profit margin vs 27.0%. RMD appears more attractively valued with a PEG of 1.29. RMD earns a higher WallStSmart Score of 67/100 (B-).
BLFS
Hold46
out of 100
Grade: D+
RMD
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.6%
Fair Value
$21.68
Current Price
$38.61
$16.93 premium
Margin of Safety
-21.1%
Fair Value
$214.32
Current Price
$239.77
$25.45 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 54 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 21.5% year-over-year
Strong operational efficiency at 30.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Generating 1.6B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
2.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Profit Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 54.3% and operating margin at 6.0%. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bear Case : BLFS
The primary concerns for BLFS are P/E Ratio, Market Cap, PEG Ratio.
Bear Case : RMD
The primary concerns for RMD are EPS Growth.
Key Dynamics to Monitor
BLFS profiles as a growth stock while RMD is a mature play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.82 — expect wider price swings.
BLFS is growing revenue faster at 21.5% — sustainability is the question.
RMD generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
RMD scores higher overall (67/100 vs 46/100), backed by strong 27.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?